The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial.

MLA

Kataoka, Ayumi, et al. “The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy May Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial.” Annals of Surgical Oncology, vol. 30, no. 6, June 2023, pp. 3224–32. EBSCOhost, https://doi.org/10.1245/s10434-023-13199-8.

APA

Kataoka, A., Sawaki, M., Horisawa, N., Kotani, H., Yoshimura, A., Hattori, M., Adachi, Y., Sugino, K., Endo, Y., Ozaki, Y., Sasaki, E., Hosoda, W., & Iwata, H. (2023). The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy may Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial. Annals of Surgical Oncology, 30(6), 3224–3232. https://doi.org/10.1245/s10434-023-13199-8

Chicago

Kataoka, Ayumi, Masataka Sawaki, Nanae Horisawa, Haruru Kotani, Akiyo Yoshimura, Masaya Hattori, Yayoi Adachi, et al. 2023. “The Absence of Cancer in the Location of a Breast Tissue Marker After Neoadjuvant Chemotherapy May Predict Pathological Complete Response with High Accuracy: Results from a Phase II Trial.” Annals of Surgical Oncology 30 (6): 3224–32. doi:10.1245/s10434-023-13199-8.